Patents Assigned to aRigen Pharmaceuticals, Inc.
-
Publication number: 20130296422Abstract: Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) (wherein, X represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; R2 represents a hydrogen atom or a C1-7 alkyl group; R3 represents —CHO, —C(?O)R5, —COOR5 (wherein R5 represents a C1-7 alkyl group), —CH2OH or —COOH; and R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.Type: ApplicationFiled: November 1, 2011Publication date: November 7, 2013Applicant: ARIGEN PHARMACEUTICALS, INC.Inventors: Hiroyuki Saimoto, Kiyoshi Kita, Yoshisada Yabu, Masaichi Yamamoto
-
Publication number: 20120321661Abstract: Provided herein is a vaccine which is safe and effective against malarial infection and a vector which is used in the manufacture of this vaccine and to provide a bivalent vaccine which exhibits an excellent preventive effect against measles virus and malarial infection and which eliminates complexity at the time of inoculation. Also provided is a recombinant measles virus in which is inserted a gene which encodes a protein involved in preventing malarial infection in the measles virus genome. The present invention also provides a bivalent vaccine against measles and malarial infection which contains the recombinant measles virus.Type: ApplicationFiled: November 20, 2009Publication date: December 20, 2012Applicant: aRigen Pharmaceuticals, Inc.Inventors: Chieko Kai, Misako Yoneda
-
Publication number: 20120263751Abstract: Provided herein is a vaccine which is safe and effective against Nipah virus infection and a vector which is used in the manufacture of this vaccine and to provide a bivalent vaccine which exhibits an excellent preventive effect against measles virus and Nipah virus infection and which eliminates complexity at the time of inoculation. Also provided is a recombinant measles virus in which is inserted a gene which encodes a protein involved in preventing Nipah infection into the measles virus genome. The protein involved in preventing Nipah virus infection is preferably G protein or F protein which is a membrane protein. Also provided is a bivalent vaccine against measles and Nipah virus infection which contains the recombinant measles virus.Type: ApplicationFiled: November 20, 2009Publication date: October 18, 2012Applicant: ARIGEN PHARMACEUTICALS, INC.Inventors: Chieko Kai, Misako Yoneda
-
Patent number: 8076302Abstract: A novel pyrimidine nucleoside derivative represented by the following formula (1) and a salt thereof, as well as a pharmaceutical composition comprising the same as an active ingredient have excellent antiviral properties and are useful as antiviral therapeutic agents: [wherein R represents a nitrogen-containing heterocyclic ring which may have any one of a C1-C3 alkyl group or a C1-C3 alkoxy group as a substituent, or a C1-C6 alkyl group which has one primary amino group as a substituent].Type: GrantFiled: February 15, 2007Date of Patent: December 13, 2011Assignee: aRigen Pharmaceuticals, Inc.Inventors: Haruhiko Machida, Masaichi Yamamoto
-
Patent number: 7868206Abstract: A compound represented by the formula (I) is used as an active ingredient in a medicament for treatment or prevention of infectious diseases caused by protozoa or bacterium. X represents halogen, Z represents —(CH2)m— wherein m is an integer of 1-5, and R represents one of the following (i)-(v): (i) hydrogen n represents an integer of 0-5, R1's independently represent hydrogen, halogen, alkoxy having 1-5 carbon atoms or alkyl having 1-5 carbon atoms. R2's independently represent hydrogen, halogen, alkoxy having 1-5 carbon atoms or alkyl having 1-5 carbon atoms. (iv) alkyl having 1-5 carbon atoms, (v) hydroxyalkyl having 1-5 carbon atoms.Type: GrantFiled: December 27, 2006Date of Patent: January 11, 2011Assignees: National University Corporation, Gunma University, National University Corporation, Nagoya Institute of Technology, Arigen Pharmaceuticals, Inc.Inventors: Tomoyoshi Nozaki, Takeshi Toru, Norio Shibata, Masaichi Yamamoto
-
Publication number: 20100234405Abstract: A novel pyrimidine nucleoside derivative represented by the following formula (1) and a salt thereof, as well as a pharmaceutical composition comprising the same as an active ingredient have excellent antiviral properties and are useful as antiviral therapeutic agents: [wherein R represents a nitrogen-containing heterocyclic ring which may have any one of a C1-C3 alkyl group or a C1-C3 alkoxy group as a substituent, or a C1-C6 alkyl group which has one primary amino group as a substituent].Type: ApplicationFiled: February 15, 2007Publication date: September 16, 2010Applicant: ARIGEN PHARMACEUTICALS, INC.Inventors: Haruhiko Machida, Masaichi Yamamoto
-
Publication number: 20100173944Abstract: Disclosed are: a compound which is stable in an acid, has an antibacterial effect against a bacterium Helicobacter pylori, can exert a satisfactory level of an antibacterial effect when used singly, does not affect an enteric bacterium, has an antibacterial effect against a bacterium resistant to an antibacterial agent, and has an inhibitory effect on gastric acid secretion; and a pharmaceutical composition comprising the compound. Specifically disclosed are: a compound represented by the general formula (I) or a salt thereof; and a pharmaceutical composition comprising the compound or the salt thereof: wherein R represents a linear alkyl group having 4 to 8 carbon atoms, preferably 5 to 7 carbon atoms.Type: ApplicationFiled: December 18, 2007Publication date: July 8, 2010Applicant: ARIGEN PHARMACEUTICALS, INC.Inventors: Masaharu Ito, Masaichi Yamamoto
-
Publication number: 20100076224Abstract: A compound represented by the formula (I) is used as an active ingredient in a medicament for treatment or prevention of infectious diseases caused by protozoa or bacterium. X represents halogen, Z represents —(CH2)m— wherein m is an integer of 1-5, and R represents one of the following (i)-(v): (i) hydrogen n represents an integer of 0-5, R1's independently represent hydrogen, halogen, alkoxy having 1-5 carbon atoms or alkyl having 1-5 carbon atoms. R2's independently represent hydrogen, halogen, alkoxy having 1-5 carbon atoms or alkyl having 1-5 carbon atoms. (iv) alkyl having 1-5 carbon atoms, (v) hydroxyalkyl having 1-5 carbon atoms.Type: ApplicationFiled: December 27, 2006Publication date: March 25, 2010Applicants: National University Corporation Gunma University, National University Corporation Nagoya Institute of Technology, Arigen Pharmaceuticals ,Inc.Inventors: Tomoyoshi Nozaki, Takeshi Toru, Norio Shibata, Masaichi Yamamoto
-
Patent number: 7622598Abstract: A compound represented by formula (I): [wherein, for example, X is a hydrogen atom or a halogen atom; R1 is a hydrogen atom; R2 is a hydrogen atom or a C1-4 alkyl group; R3 is —CHO or —COOH; and R4 is —CH?CH—(CH2)p—CH3 (wherein p is an integer of 1 to 12), —CH(OH)—(CH2)q—CH3 (wherein q is an integer of 1 to 13), —CH(OH)—CH2—CH(CH3)—(CH2)2—CH?C(CH3)2, —CH?CH—CH(CH3)—(CH2)3—CH(CH3)2, —(CH2)2—CH(CH3)—(CH2)3—CH(CH3)2 or —(CH2)8—CH3], an optical isomer thereof and a pharmaceutically acceptable salt thereof. These compounds have antitrypanosoma activity, and accordingly are useful as drugs for preventing or treating the diseases caused by trypanosoma.Type: GrantFiled: October 18, 2004Date of Patent: November 24, 2009Assignee: aRigen Pharmaceuticals, Inc.Inventors: Hiroyuki Saimoto, Yoshihiro Shigemasa, Kiyoshi Kita, Yoshisada Yabu, Tomoyoshi Hosokawa, Masaichi Yamamoto
-
Patent number: 7618950Abstract: A method for the treatment and prevention of herpes zoster using 5-[(E)-2-halogenovinyl] arabinofuranosyl uracil of the following general formula (1): wherein X represents a halogen atom.Type: GrantFiled: July 7, 2004Date of Patent: November 17, 2009Assignee: aRigen Pharmaceuticals, Inc.Inventors: Masaichi Yamamoto, Haruhiko Machida
-
Publication number: 20090258920Abstract: A pharmaceutical composition for injection comprising a depsipeptide antibiotic, WAP-8294A2, as an active ingredient, which is stable and contains WAP-8294A2 in high concentrations is provided. This composition comprises WAP-8294A2 of the following structural formula (1) as an active ingredient and is characterized in that 2-hydroxypropyl-?-cyclodextrin or ?-cyclodextrin is contained as a stabilizer or solubilizer and the pH of the composition is not adjusted. This composition is mixed with a pH-adjusting agent such as dextrose and with an infusion or diluent comprising a solution of disodium hydrogen phosphate, sodium dihydrogen phosphate, and sodium hydroxide at the time of use to prepare a solution for intravenous administration of WAP-8294A2.Type: ApplicationFiled: June 28, 2007Publication date: October 15, 2009Applicant: aRIGEN PHARMACEUTICALS, INC.Inventors: Hirofumi Nakajima, Haruhiko Machida
-
Publication number: 20090143438Abstract: The object is to provide an excellent pharmaceutical having an anti-Helicobacter pylori activity. Disclosed is a novel pyridine derivative represented by the following general formula (I): wherein R represents a linear or branched hydroxyalkyl group having 5 to 10 carbon atoms, or a pharmaceutically acceptable salt thereof, which has a potent antibacterial activity against H. pyroli (Helicobacter pyroli) Examples of the disease which can be prevented/treated by administration of a pharmaceutical agent comprising the compound include gastritis, gastric ulcer, duodenal ulcer, gastric MALT lymphoma, gastric hyperplastic polyp, development of gastric cancer after endoscopic resection of the early stage of gastric cancer and the like.Type: ApplicationFiled: March 7, 2007Publication date: June 4, 2009Applicant: Arigen Pharmaceuticals, Inc.Inventors: Masaharu Ito, Masaichi Yamamoto
-
Patent number: 7495011Abstract: The present invention provides an anti-coronavirus agent including as an active ingredient as exemplified by nelfinavir and salts thereof, an anti-SARS agent including the anti-coronavirus agent, and a method of treating SARS using the anti-SARS agent.Type: GrantFiled: July 14, 2004Date of Patent: February 24, 2009Assignee: aRigen Pharmaceuticals, Inc.Inventors: Nobutaka Fujii, Naoki Yamamoto